Simcha Therapeutics
New Haven, US · Delaware LLC · 8 employees on LinkedIn · 10 known investors
Find your way into Simcha Therapeutics
Simcha is a biotechnology company developing new cancer medicines based on immune biology research. It focuses on translating discoveries in immune biology into oncology drugs for patients with cancer.
Founders & leadership
AR
BM
Beatrice McQueeninChief Operating Officer (Life Science)
SR
Sanuj RavindranChief Executive Officer
JB
Jeremy BartonChief Medical Director
HU
Hirdesh UppalSenior Vice President Translational Research and Development Sciences
JC
Joseph CatinoNamed on SEC filing
Board
YL
Yiming LiBoard director
JB
Jake BauerinChairman of the BoardVenture Partner - US Investments/New Company Creation at SR One Capital Management
RS
Richard SollManager
AH
Axel HoosBoard director
TR
Terry RosenBoard director
Investors · 10
Connecticut InnovationsNew Haven · $500K – $2M
Pfizer Venture Investments$5M – $20M
SR One Capital ManagementRedwood City
Axial VCreportedSan Francisco · $100K – $5M
Biotechnology Value FundreportedSan Francisco
Rock Springs CapitalreportedBaltimore
Samsara BioCapitalreportedPalo Alto
Also in the syndicate · 3
ArrowMark PartnersLogos CapitalSR Onelead
Reported raises · per SEC filings
Form D private placements$68.1M disclosed across 4 rounds · 2018–2025
▶$7.1MraisedJun 2025 · 5 investors · BiotechnologyRule 506(b)
▶$7.1MraisedJun 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yiming LiDirector
- Axel HoosDirector
- Terry RosenDirector
- Aaron RingExecutive Officer, Director
- Jake BauerExecutive Officer, Director
- Beatrice McQueenExecutive Officer
- Sanuj RavindranExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $7.1M
- First sale
- Jun 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$40MraisedSep 2021 · 14 investors · BiotechnologyRule 506(b)
▶$40MraisedSep 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simeon GeorgeDirector
- Terry L. RosenDirector
- Aaron RingExecutive Officer, Director
- Lennart H. LeeDirector
- Beatrice McQueenExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Aug 2021
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$16.6MraisedMay 2020 · 14 investors · BiotechnologyRule 506(b)
▶$16.6MraisedMay 2020 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RingExecutive Officer, Director
- Terry L. RosenDirector
- Lennart H. LeeDirector
- Gu CuipingDirector
- Beatrice McQueenExecutive Officer
- Offering amount
- $25.6M
- Amount sold
- $16.6M
- First sale
- May 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$4.4MraisedJul 2018 · 9 investors · BiotechnologyRule 506(b)
▶$4.4MraisedJul 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard SollDirector
- Terry RosenDirector
- Aaron RingExecutive Officer, Director
- Joseph CatinoExecutive Officer
- Offering amount
- $6M
- Amount sold
- $4.4M
- First sale
- Jul 2018
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Solu6 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Fred Hutch6 shared keywordsFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
Shape Therapeutics5 shared keywordsShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
Companies competing with Simcha Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Simcha Therapeutics do?
- Simcha is a biotechnology company developing new cancer medicines based on immune biology research. It focuses on translating discoveries in immune biology into oncology drugs for patients with cancer.
- Who founded Simcha Therapeutics?
- Simcha Therapeutics was founded by Aaron Ring.
- Who are Simcha Therapeutics's investors?
- Simcha Therapeutics's investors include Connecticut Innovations, Pfizer Venture Investments, SR One Capital Management, Axial VC, Biotechnology Value Fund, Rock Springs Capital, Samsara BioCapital.
- How much funding has Simcha Therapeutics raised?
- Simcha Therapeutics has disclosed $68.1M raised across 4 rounds.
- Where is Simcha Therapeutics headquartered?
- Simcha Therapeutics is headquartered in New Haven, US.